Article
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis.
Molecular cancer - 17 Mar 2023
Njouendou Abdel Jelil, Szarvas Tibor, Tiofack Arnol Auvaker Zebaze, Kenfack Rovaldo Nguims, Tonouo Pamela Derliche, Ananga Sidonie Noa, Bell Esther H M Dina, Simo Gustave, Hoheisel Jörg D, Siveke Jens T, Lueong Smiths S
Abstract excerpt
BACKGROUND: Inflammation is undoubtedly a hallmark of cancer development. Its maintenance within tumors and the consequences on disease aggressiveness are insufficiently understood. METHODS: Data of 27 tumor entities (about 5000 samples) were downloaded from the TCGA and GEO databases. Multi-omic analyses were performed on these and in-house data to investigate molecular determinants of tumor aggressiveness....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.